Bluebird Bio
Presence
Bluebird Bio is one of the...
Bluebird Bio is a company listed under the stock ticker BLUE (US).
Executives
View the org chart displaying its 31 main executives
Most searched biographies at Bluebird Bio
Popular executive movements at Bluebird Bio
- Sharon Bosdet has joined the company as Head of Total Rewards and Human Resources Operations (posted on October 25 2023).
Create your alert
to follow the executive moves at Bluebird Bio.
Biotechnology
Bluebird Bio has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Bluebird Bio
- press releases | bluebird bio, Inc.
- FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions | bluebird bio, Inc.
- FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy | bluebird bio, Inc.
- bluebird bio stock trading halted today June 9th and tomorrow June 10th | bluebird bio, Inc.
- bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting | bluebird bio, Inc.
- bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress | bluebird bio, Inc.
- bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) - bluebird bio, Inc.
- bluebird bio to Present at Jefferies Cell Therapy Virtual Summit - bluebird bio, Inc.
- bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency - bluebird bio, Inc.
- U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) - bluebird bio, Inc.
- View more press releases Close
Social media about Bluebird Bio
- Bluebird Bio on Wikipedia, Google News & Yahoo Finance
- Bluebird Bio on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Andrew Obenshain 
Call Bluebird Bio at +1 339...
